Today, diabetes management requires a combination of medications and lifestyle changes. This is a physical, emotional and financial burden on millions of people with diabetes and their caregivers.
When we digest food, sugar is released into our blood. That sugar needs to be absorbed into the body and used for energy. Beta cells in the pancreas make and secrete insulin, which, in turn, allows the body to absorb glucose (sugar) from the blood.
TYPE I DIABETES
The body’s own immune system attacks the cells, damaging them until they cannot do their job producing insulin. There is no cure.
TYPE II DIABETES
Beta cells do produce insulin but the body can’t take advantage of it to get the job done. It is often caused by obesity, smoking and other unhealthy behaviors. For 30% that are suffering from insulin deficiency, there is no cure.
EMP (for Clinical Market)
- Working as a ‘Micro Pancreas’ ensuring long-term insulin secretion
- Reduces the need for repeated transplantations
- Simplified procedure allowing widespread implementation
- Enduring insulin production
EMP1R (FOR RESEARCH MARKET)
- The EMP1 r technology improves existing tests for the diabetes drug discovery market.
- Consistent planning of long-term R&D Processes
- Reduces the drug development costs
- Fills existing supply gap between R&D spending for diabetes and demand for human
We are Hiring!
Betalin is currently raising capital to further optimize the theraphy and complete submission of the New Drug (IND) application to the FDA and start clinical trials. Learn more about how we can revolutionize diabetes treatment today.
Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development. Based on promising in vitro results and preliminary in vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA’s positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.
EXPERIENCED EXECUTIVES. EXPERTS IN THE FIELD OF DIABETES AND BIOTECH. ALL WORKING TOGETHER.